Eton Q1 Beats, Raises Guidance; DESMODA Launch and HEMANGEOL Acquisition Drive Growth

What happened

Eton Pharmaceuticals reported Q1 2026 product sales of $24.3 million, a 73% increase year-over-year, and raised full-year revenue guidance to over $120 million from $110 million. The company achieved GAAP EPS of $0.05 and non-GAAP EPS of $0.14, with Adjusted EBITDA of $5.7 million, reflecting improved operational leverage. Key milestones included the FDA approval and launch of DESMODA for central diabetes insipidus, the acquisition and relaunch of HEMANGEOL, and progress on ET-700 and INCRELEX studies. While the strong quarterly performance reduces near-term liquidity concerns, the company still faces critical execution events: the May 1 HEMANGEOL distributor transition and the conversion of DESMODA prescriptions from bridge to paid fills. The guidance raise suggests management confidence, but the sustainability of profitability depends on smooth post-transition operations and payer coverage for DESMODA.

Implication

The Q1 beat and raised guidance improve the near-term outlook and may support the stock, but investors should remain cautious given the tight margin for error. The company must now demonstrate that the HEMANGEOL transition on May 1 proceeds without disruption and that DESMODA begins to show paid-fill conversion. Additionally, quarterly SWK debt amortization of $3 million starts in May, and cash flow must cover this alongside launch investments. The bull case ($30) relies on these events; the bear case ($12) warns of operational slippage. Therefore, while the Q1 data is encouraging, we maintain a wait stance until we see evidence of sustained execution in Q2.

Thesis delta

The Q1 results and guidance raise modestly increase the probability of the base case ($21), as revenue momentum and profitability reduce immediate financing fears. However, the core thesis remains unchanged: the stock's next move depends on two date-stamped events—HEMANGEOL handoff and DESMODA conversion. Until those are resolved, the risk/reward is balanced, limiting upside without proof of execution.